CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.

Daratumumab (1,800mg) will be administered by a subcutaneous injection once every week for 2 cycles (Cycles 1-2), then once every 2 weeks for 4 cycles (Cycles 3-6), and following this (Cycle 7 onwards), patients will receive daratumumab once every four weeks.

Cyclophosphamide will be administered PO at 50mg daily for all cohorts in the study.

Pomalidomide will be administered PO on days 1-21 of each 28 day cycle. The dose will be specified by the dose level to which the patient has been enrolled.

Dexamethasone will be administered PO at 40mg on days 1, 8, 15 and 22 of each 28 day cycle.